ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer
But Tecentriq/Avastin Looms In 1L HCC
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
